孙剑

南方医院院长

二级教授/主任医师

个人简介

孙剑，1974年出生，第十四届全国人大代表，南方医科大学南方医院院长，二级教授，主任医师，博士生导师，教育部长江学者特聘教授，科技部中青年科技创新领军人才，广东省珠江学者特聘教授，广东省杰出青年医学人才，现任中华医学会感染病学分会委员、中华医学会肝病学分会肝炎学组副组长和广东省医学会感染病学分会第十届委员会候任主任委员等。

主要从事慢性肝病的基础和临床研究，通过组织开展多中心、随机对照临床研究并结合分子病毒学和免疫学研究，在乙型肝炎的发病机制、抗病毒治疗、肝硬化和肝癌的早期诊断及防治方面做出创新性贡献。

共发表SCI论文127篇，影响因子合计 998.284，第一或通讯作者发表论文61篇，代表作包括Nature Medicine（2020，共同第一）、Hepatology（2022，最后通讯）、J Hepatol（2020，共同第一）、Hepatology（2021，共同通讯）等。4篇代表作被2015年亚太和中国乙肝防治指南引用并作为推荐意见。获得专利授权三项（2021，《基于HBV S区的高敏HBV RNA定量检测的引物探针组合物、试剂盒及其应用》专利号：ZL 202110198820.6；2022，《长链酰基肉碱类化合物在制备预防和/或治疗肝癌的药物中的应用 》专利号：ZL 202210885704.6；2024，《生孢梭菌在制备预防和/或治疗肝脏疾病的药物中的应用》专利号ZL20241 0091497.6）。

主持国家自然科学基金重点项目、国家重点研发计划专项项目，国家自然科学基金联合基金重点项目，国家自然科学基金面上项目共5项，广东省重点领域研发计划项目1项，广东省区域联合重点项目1项和广州市科技计划项目重点项目各1项。近年获广东省科技进步一等奖1项（2023年第一完成人）、广东省“丁颖科技奖”（2021年）、2017年获“羊城好医生”荣誉称号。国家科技进步二等奖1项（2015年第四完成人），广东省科技进步一等奖1项（2017年第一完成人），吴孟超医学青年基金奖（2018年）、中华医学科技二等奖1项（2014年第二完成人）。2012和2013年两次获得亚太肝病学会青年研究者奖，2013年获得广东省青年五四奖章提名奖。2014和2017年作为大会秘书长成功组织第4届亚太肝病学会乙肝专题会议和第26届亚太肝病学会年会。

担任欧洲肝病学会官方杂志Journal of Hepatology编委、美国胃肠病学会官方杂志Clinical Gastroenterology and Hepatology杂志编委、国际肝病研究协会官方杂志Liver International杂志副主编和Journal of Medical Virology杂志副主编、WILEY杂志客座编辑、《实用肝脏病杂志》副主编、《中国病毒病杂志》编委、《临床肝胆病杂志》编委。

研究领域

主要从事肠道菌群、乙肝病毒、宿主代谢物在慢性肝病和肝癌中的作用和机制研究

个人成果

一、主持或参加科研项目（课题）情况（按时间倒序排序）

1.国家自然科学基金重点项目，批准号82430025，运动诱导的肠乳杆菌通过代谢产物吲哚-3-羧酸调控TRIM63-PPARα轴改善非酒精性脂肪性肝病的作用与机制研究，2025.01.01-2029.12.31,229万，在研，主持

2.广州市科技重点研发计划，2024B03J0326，慢性乙型肝炎向肝癌转归的调控机制及干预靶点研究，2024.01.01-2026.12.31,50万，在研，主持

3. 广东省重点领域研发计划，2023B1111030005，针对慢性乙型肝炎治愈的干预靶点鉴定及新药研发，2023.01.01-2026.01.01,500万，在研，主持

4. 国家自然科学基金联合基金重点支持项目，U22A20274，功能性代谢物在慢性乙型肝炎疾病进展中的作用及其分子机制，2023.01.01 -2026.12.31，255万，在研，主持；

5. 国家重点研发计划，2022YFC2304800，重大传染性疾病重症患者的全病程智能管理，2022.12-2025.11，2000万，在研，主持；

6. 广东省基础与应用基础研究基金区域联合基金重点项目，2022B1515120039，慢性乙型肝炎疾病进展的调控机制及干预靶点研究，2022.10.01-2025.09.30，100万，在研，主持；

7. 广州市科技计划重点研发计划，202206080001，靶向宿主免疫和病毒cccDNA的慢性乙肝治愈的新机制新靶点新策略临床转化研究，子课题负责人，2022.04-2025.03，100万元，在研，主持；

8. 国家自然科学基金面上项目，82070614，HBV pgRNA病毒样颗粒侵入肝细胞并形成持续感染能力的研究，2021.01-2024.12，55万元，在研，主持；

9. 国家自然科学基金面上项目，81871668，宿主E3泛素连接酶TRIM65抑制乙肝病毒复制的作用及机制研究，2019.01-2022.12，57万元，结题，主持；

10. 广州市科技计划项目重点项目专题，201804020001，乙型肝炎核心抗体精准分析及其预测抗病毒治疗应答的免疫学机制，2018.04-2021.03，200万元，结题，主持；

11. 十三五国家科技重大专项，2017ZX1020220-004/005，免疫调节/抗病毒联合治疗新方案提高慢性乙型肝炎临床治愈率及其对远期转归影响的研究，2017.01-2020.12，2707.59万元，结题，主持；

12. 珠江学者（特聘教授），病原生物学，2017.10-2022.09，100万元，结题，主持；

13. 广东省“珠江人才计划”本土创新科研团队，2017BT01S131，慢性肝病精准医学创新团队，2018.04-2023.03，总经费2000万元（个人支配经费200万元），在研，第一核心成员主持；

14. 广东省自然科学基金面上项目，2016A030313550，Anti-HBc 定量与乙肝抗病毒治疗应答和持久免疫控 制的关系及其机制探讨，2016.06-2019.06，10万元，结题，主持；

15. 广州市科技计划项目健康医疗协同创新重大专项，201604020002，慢性肝病预警新生标志物的筛选、鉴定及临床引用，2015.10-2018.09，120万元，结题，主持；

16. 中华医学会项目，13071100495，一项探索聚乙二醇干扰素（Peg-IFN)治疗慢性乙型病毒性肝炎患者疗效相关预测因素的研究，2014.01-2015.12，100万元，已结题，主持；

17. 十二五国家科技重大专项，2012ZX10002003-001-001，基于国产干扰素联合乙肝疫苗等优化治疗方案，2012.01-2015.12，459.61万元，已结题，主持；

18. 十一五国家科技重大专项，2009ZX10004-314，乙型肝炎病毒表型分析技术和耐药网络的建立及应用，2009.01-2010.12，158万元，已结题，主持；

二、代表性论著

1. Huang Q, Zhou B, Cai DW, Zong YH, Wu YB, Liu S, Mercier A, Guo HT, Hou JL, Colonno R, Sun J (corresponding author). Rapid Turnover of HBV cccDNA Indicated by Monitoring Emergence and Reversion of Signature-Mutation in Treated Chronic Hepatitis B Patients. Hepatology. 2021 Jan;73(1):41-52. doi: 10.1002/hep.31240. (IF: 17.425; Q1) （代表作之十一）

2. Xu X, Sun J (co-first author), Nie S, Li H, Kong Y, Liang M, Hou J, Huang X, Li D, Ma T, Peng J, Gao S, Shao Y, Zhu H, Lau JY, Wang G, Xie C, Jiang L, Huang A, Yang Z, Zhang K, Hou FF. Seroprevalence of immunoglobulin M and G antibodies against SARS-CoV-2 in China. Nat Med. 2020 Aug;26(8):1193-1195. doi: 10.1038/s41591-020-0949-6. Epub 2020 Jun 5. PMID: 32504052 (IF: 53.44; Q1) （代表作之十）

3. Fan R, Chen L, Zhao S, Yang H, Li Z, Qian Y, Ma H, Liu X, Wang C, Liang X, Bai J, Xie J, Fan X, Xie Q, Hao X, Wang C, Yang S, Gao Y, Bai H, Dou X, Liu J, Wu L, Jiang G, Xia Q, Zheng D, Rao H, Xia J, Shang J, Gao P, Xie D, Yu Y, Yang Y, Gao H, Liu Y, Sun A, Jiang Y, Yu Y, Niu J, Sun J(co-corresponding author), Wang H, Hou J. Novel, high accuracy models for hepatocellular carcinoma prediction based on longitudinal data and cell-free DNA signatures. J Hepatol. 2023 Jun 10:S0168-8278(23)00416-6. doi: 10.1016/j.jhep.2023.05.039. Epub ahead of print. PMID: 37302583. (IF: 25.7; Q1) （代表作之九）

4. Fan R, Papatheodoridis G, Sun J (co-first author), Innes H, Toyoda H, Xie Q, Mo S, Sypsa V, Guha IN, Kumada T, Niu J, Dalekos G, Yasuda S, Barnes E, Lian J, Suri V, Idilman R, Barclay ST, Dou X, Berg T, Hayes PC, Flaherty JF, Zhou Y, Zhang Z, Buti M, Hutchinson SJ, Guo Y, Calleja JL, Lin L, Zhao L, Chen Y, Janssen H, Zhu C, Shi L, Tang X, Gaggar A, Wei L, Jia J, Irving WL, Johnson PJ, Lampertico P, Hou J. aMAP risk score predicts hepatocellular carcinoma development in chronic hepatitis patients: an international cohort collaboration. J Hepatol. 2020 Dec;73(6):1368-1378. doi: 10.1016/j.jhep.2020.07.025. (IF: 25.083; Q1) （代表作之八）

5. Sun J, Ma H, Xie Q, Xie Y, Sun Y, Wang H, Shi G, Wan M, Niu J, Ning Q, Yu Y, Zhou H, Chen J, Kang W, Xie Y, Fan R, Wel L, Zhuang H, Jia J, Hou J. Response-guided peginterferon therapy in patients with HBeAg positive chronic hepatitis B: A randomized controlled study. Journal of Hepatology. 2016 Oct; 65(4): 674-682. (IF: 25.083; Q1) （代表作之七）

6. Fan R, Sun J (co-first author), Yuan Q, Xie Q, Bai XF, Ning Q, Cheng J, Yu YY, Niu JQ, Shi GF, Wang H, Tan DM, Wan MB, Chen SJ, Xu M, Chen XY, Tang H, Sheng JF, Lu FM, Jia JD, Zhuang H, Xia NS, Hou JL. Chronic Hepatitis B Study Consortium. Baseline Quantitative Hepatitis B Core Antibody Titer Alone Strongly Predicts HBeAg Seroconversion across Chronic Hepatitis B Patients Treated with Peg-Interferon or Nucleos(t)ide Analogues. Gut. 2016 Feb; 65(2): 313-332. (IF: 19.819; Q1) （代表作之六）

7. Sun J, Xie Q, Tan D, Ning Q, Niu J, Bai X, Fan R, Chen S, Cheng J, Yu Y, Wang H, Xu M, Shi G, Wan M, Chen X, Tang H, Sheng J, Dou X, Shi J, Ren H, Wang M, Zhang H, Gao Z, Chen C, Ma H, Jia J, Hou J. 104-week efficacy and safety of telbivudine based optimization strategy in chronic hepatitis B patients: A randomized, controlled study. Hepatology, 2014 Apr;59(4):1283-1292. (IF: 17.425; Q1) （代表作之五）

8. Liu S, Zhou B, Valdes JD, Sun J (co-corresponding author), Guo H. Serum HBV RNA: a New Potential Biomarker for Chronic Hepatitis B Virus Infection. Hepatology. 2019 Feb. 69(4): 1816-1827. (IF: 17.425; Q1) （代表作之四）

9. Deng R, Liu S, Shen S, Guo H, Sun J (co-corresponding author). Circulating hepatitis B virus RNA: From biology to clinical applications. Hepatology. 2022 Mar 28. doi: 10.1002/hep.32479. (IF: 17.425; Q1) （代表作之三）

10. Liu S, Liu Z, Li W, Zhou B, Liang X, Fan R, Deng R, Hou J, Sun J (corresponding author). Factors associated with the biphasic kinetics of serum HBV RNA in patients with HBeAg-positive chronic hepatitis B treated with nucleos(t)ide analogues. Aliment Pharmacol Ther. 2020 Aug;52(4):692-700. doi: 10.1111/apt.15890. Epub 2020 Jul 1. (IF: 8.171; Q1) （代表作之二）

11. Shen S, Xie Z, Cai D, Yu X, Zhang H, Kim ES, Zhou B, Hou J, Zhang X, Huang Q, Sun J (co-corresponding author), Guo H. Biogenesis and molecular characteristics of serum hepatitis B virus RNA. PLoS Pathog. 2020 Oct 20;16(10):e1008945. doi: 10.1371/journal.ppat.1008945. (IF: 6.823; Q1)（代表作之一）

三、已发表的其余论著

1. Liu S, Wong GL, Fan R, Niu J, Ma H, Liang W, Lu X, Xie J, Shang J, Xie D, Liu Y, Zhou B, Xie Q, Peng J, Gao H, Rao H, Chen J, Sheng J, Shen S, Yang S, Dou X, Zhang Z, Wong VW, Hou J, Sun J. Role of Early On-Treatment Serum HBV RNA Declines in Predicting Hepatocellular Carcinoma Risk in Patients With Chronic Hepatitis B. Clin Gastroenterol Hepatol. 2024 Aug 23:S1542-3565(24)00758-4. doi: 10.1016/j.cgh.2024.07.024.

2. Zheng D, Cheng C, Tang Y, Fang Z, Gao X, Chen Y, You Q, Wang K, Zhou H, Lan Z, Sun J. Circulating metabolites are associated with persistent elevations of ALT in patients with chronic hepatitis B with complete viral suppression. J Med Virol. 2024 Jun;96(6):e29723. doi: 10.1002/jmv.29723

3. Zhang KK, Yang JZ, Cheng CH, Wan JY, Chen YC, Zhou HQ, Zheng DK, Lan ZX, You QH, Wang Q, Sun J. Short-chain fatty acids mitigate Methamphetamine-induced hepatic injuries in a Sigma-1 receptor-dependent manner. Ecotoxicol Environ Saf. 2024 Jun 3;280:116538. doi: 10.1016/j.ecoenv

4. Shen S, Yan R, Xie Z, Yu X, Liang H, You Q, Zhang H, Hou J, Zhang X, Liu Y, Sun J (co-corresponding author), Guo H. Tripartite Motif-Containing Protein 65 (TRIM65) Inhibits Hepatitis B Virus Transcription. Viruses. 2024 May 31;16(6):890. doi: 10.3390/v16060890.

5. Zhang KK, Wan JY, Chen YC, Cheng CH, Zhou HQ, Zheng DK, Lan ZX, You QH, Sun J. Polystyrene nanoplastics exacerbate aflatoxin B1-induced hepatic injuries by modulating the gut-liver axis. Sci Total Environ. 2024 May 19;935:173285. doi: 10.1016/j.scitotenv.2024.173285

6. Lu X, Li W, Deng R, Zhou B, Yu R, Hou J, Shen S, Sun J (corresponding author), Liu S. Serum hepatitis B virus spliced RNA proportion increases with liver disease progression in patients with chronic hepatitis B. J Med Virol. 2024 Feb;96(2):e29400. doi: 10.1002/jmv.29400

7. Zhou H, Shi S, You Q, Zhang K, Chen Y, Zheng D, Sun J (corresponding author). Polyethylene Terephthalate Hydrolases in Human Gut Microbiota and Their Implications for Human Health. Microorganisms. 2024 Jan 10;12(1):138. doi: 10.3390/microorganisms12010138.

8. Chen L, Wu T, Fan R, Qian YS, Liu JF, Bai J, Zheng B, Liu XL, Zheng D, Du LT, Jiang GQ, Wang YC, Fan XT, Deng GH, Wang CY, Shen F, Hu HP, Zhang QZ, Ye YN, Zhang J, Gao YH, Xia J, Yan HD, Liang MF, Yu YL, Sun FM, Gao YJ, Sun J, Zhong CX, Wang Y, Wang H, Kong F, Chen JM, Wen H, Wu BM, Wang CX, Wu L, Hou JL, Wang HY. Cell-free DNA testing for early hepatocellular carcinoma surveillance. EBioMedicine. 2024 Jan 6;100:104962. doi: 10.1016/j.ebiom.2023.104962.

9. Fan R, Yu N, Li G, Arshad T, Liu WY, Wong GL, Liang X, Chen Y, Jin XZ, Leung HH, Chen J, Wang XD, Yip TC, Sanyal AJ, Sun J, Wong VW, Zheng MH, Hou J. Machine-learning model comprising five clinical indices and liver stiffness measurement can accurately identify MASLD-related liver fibrosis. Liver Int. 2023 Dec 22. doi: 10.1111/liv.15818.

10. Chen P, Dong Z, Zhu W, Chen J, Zhou Y, Ye Q, Liao X, Tan Y, Li C, Wang Y, Pang H, Wen C, Jiang Y, Li X, Li B, Aimaier A, Lin L, Sun J, Hou J, Tang L, Hou J, Li Y. Noncanonical regulation of HOIL-1 on cancer stemness and sorafenib resistance identifies pixantrone as a novel therapeutic agent for hepatocellular carcinoma. Hepatology. 2023 Oct 11. doi: 10.1097/HEP.0000000000000623. Epub ahead of print.

11. Ye Z, Liu M, He P, Wu Q, Yang S, Zhang Y, Zhou C, Zhang Y, Gan X, Sun J (co-corresponding author), Qin X. Various ambient air pollutants, residential green spaces, fibrosis 4 scores, genetic susceptibility, and risk of severe liver disease. Ecotoxicol Environ Saf. 2023 Sep 15;263:115246. doi: 10.1016/j.ecoenv.2023.115246.

12. Shen S, Liu W, Zeng G, Liang H, Yu X, Zhang H, Sun J(co-corresponding author), Guo H. Conditional replication and secretion of hepatitis B virus genome uncover the truncated 3' terminus of encapsidated viral pregenomic RNA. J Virol. 2023 Sep 27;97(10):e0076023. doi: 10.1128/jvi.00760-23.

13. Deng R, Wang Z, Liu Y, Sun J(corresponding author). Letter to the Editor: Cautious interpretation of the association between finite treatment and better prognosis in initially HBeAg-negative hepatitis B patients with cirrhosis. Hepatology. 2023 Oct 31. doi: 10.1097/HEP.0000000000000654.

14. Zheng D, Fang Z, Sun J(corresponding author). Which Is More Clinically Relevant: End-of-Treatment or Off-Treatment Predictors of Hepatitis B Relapse and Surface Antigen Loss? Gastroenterology. 2023 Oct26 :S00165085(23)05196X.doi:10.1053/j.gastro.2023.10.020.

15. Chen J, Lou S, Chen H, Zhou B, Sun J, Hou J, Jiang DK. CD55 Variant Associated with Pegylated-interferon α Therapy Response in HBeAg-positive Chronic Hepatitis B Patients. J Clin Transl Hepatol. 2023 Apr 28;11(2):295-303. doi: 10.14218/JCTH.2022.00057.

16. Fan R, Li G, Yu N, Chang X, Arshad T, Liu WY, Chen Y, Wong GL, Jiang Y, Liang X, Chen Y, Jin XZ, Dong Z, Leung HH, Wang XD, Zeng Z, Yip TC, Xie Q, Tan D, You S, Ji D, Zhao J, Sanyal AJ, Sun J, Zheng MH, Wong VW, Yang Y, Hou J. aMAP Score and Its Combination With Liver Stiffness Measurement Accurately Assess Liver Fibrosis in Chronic Hepatitis B Patients. Clin Gastroenterol Hepatol. 2023 Mar 17:S1542-3565(23)00185-4. doi: 10.1016/j.cgh.2023.03.005.

17. Li Y, Wen C, Gu S, Wang W, Guo L, Li CK, Yi X, Zhou Y, Dong Z, Fu X, Zhong S, Wang Y, Huang K, Yin J, Zhong C, Liang X, Fan R, Chen H, Jiang D, Zhang X, Sun J, Tang L, Peng J, Hou J. Differential response of HBV envelope-specific CD4 + T cells is related to HBsAg loss after stopping nucleos(t)ide analogue therapy. Hepatology. 2023 Mar 13. doi: 10.1097/HEP.0000000000000334.

18. Fan R, Chen L, Zhao S, Yang H, Li Z, Qian Y, Ma H, Liu X, Wang C, Liang X, Bai J, Xie J, Fan X, Xie Q, Hao X, Wang C, Yang S, Gao Y, Bai H, Dou X, Liu J, Wu L, Jiang G, Xia Q, Zheng D, Rao H, Xia J, Shang J, Gao P, Xie D, Yu Y, Yang Y, Gao H, Liu Y, Sun A, Jiang Y, Yu Y, Niu J, Sun J(co-corresponding author), Wang H, Hou J. Novel, high accuracy models for hepatocellular carcinoma prediction based on longitudinal data and cell-free DNA signatures. J Hepatol. 2023 Jun 9:S0168-8278(23)00416-6. doi: 10.1016/j.jhep.2023.05.039. Epub ahead of print. PMID: 37302583.

19. Wu T, Fan R, Bai J, Yang Z, Qian YS, Du LT, Wang CY, Wang YC, Jiang GQ, Zheng D, Fan XT, Zheng B, Liu JF, Deng GH, Shen F, Hu HP, Ye YN, Zhang QZ, Zhang J, Gao YH, Xia J, Yan HD, Liang MF, Yu YL, Sun FM, Gao YJ, Sun J, Zhong CX, Wang Y, Wang H, Kong F, Chen JM, Wen H, Wu BM, Wang CX, Wu L, Hou JL, Liu XL, Wang HY, Chen L. The development of a cSMART-based integrated model for hepatocellular carcinoma diagnosis. J Hematol Oncol. 2023 Jan 5;16(1):1. doi: 10.1186/s13045-022-01396-z.

20. Xie Z, Shen S, Huang K, Wang W, Liu Z, Zhang H, Lu M, Sun J, Hou J, Liu H, Guo H, Zhang X. Mitochondrial HIGD1A inhibits hepatitis B virus transcription and replication through the cellular PNKD-NF-κB-NR2F1 nexus. J Med Virol. 2023 Apr;95(4):e28749. doi: 10.1002/jmv.28749.

21. Tang Y, Fan R, Lan Z, Xie Q, Zhang J, Liang X, Wang H, Tan D, Cheng J , Chen S, Ning Q, Bai X, Xu M, Chen X, Niu J, Shi J, Ren H, Gao Z, Wang M, Dou X, Hou J, Sun J(co-corresponding author). Impact of nonalcoholic fatty liver disease status change on antiviral efficacy of nucleos(t)ide analogues in HBeAg-positive chronic hepatitis B. J Med Virol. 2023 Jan 19. doi: 10.1002/jmv.28501.

22. Sun J (first author & corresponding author), Tanaka J, Valenti L. The changing epidemiology of liver diseases in Asia. Liver Int. 2022 Aug;42(9):1926-1929. doi: 10.1111/liv.15354. PMID: 35869571.

23. Yuan G, Xie F, Song Y, Li Q, Li R, Hu X, Zang M, Cheng X, Lu G, Huang J, Fan W, Rong X, Sun J (co-corresponding author), Chen J. Hepatic Tumor Stiffness Measured by Shear Wave Elastography Is Prognostic for HCC Progression Following Treatment With Anti-PD-1 Antibodies Plus Lenvatinib: A Retrospective Analysis of Two Independent Cohorts. Front Immunol. 2022 Jun 9;13:868809. doi: 10.3389/fimmu.2022.868809. PMID: 35757765; PMCID: PMC9218245..

24. Liu S, Li Y, Sun J (corresponding author). Concerns about the inverse relationship between baseline HBV DNA and on-treatment hepatocelluar carcinoma risk. J Clin Invest. 2022.

25. Deng R, Fan R, Sun J (corresponding author). Letter to the Editor: Probability of HBsAg loss after nucleo(s)tide analogue withdrawal depends on HBV genotype and viral antigen levels. Journal of Hepatology. 2022.

26. Tang Y, Liang H, Zeng G, Shen S, Sun J (corresponding author). Advances in new antivirals for chronic hepatitis B. Chin Med J (Engl). 2022 Feb 2;135(5):571-583. doi: 10.1097/CM9.0000000000001994.

27. Fan R, Niu J, Ma H, Xie Q, Cheng J, Rao H, Dou X, Xie J, Zhao W, Peng J, Gao Z, Gao H, Chen X, Chen J, Li Q, Tang H, Zhang Z, Ren H, Cheng M, Liang X, Zhu C, Wei L, Jia J, Sun J (co-corresponding author), Hou J; Chronic Hepatitis B Study Consortium. Association of central obesity with hepatocellular carcinoma in patients with chronic hepatitis B receiving antiviral therapy. Aliment Pharmacol Ther. 2021 Aug;54(3):329-338. doi: 10.1111/apt.16469.

28. Zhang X, Lu S, Li H, Wang Y, Lu Z, Liu Z, Lai Q, Ji Y, Huang X, Li Y, Sun J, Wu Y, Xu X, Hou J. Viral and Antibody Kinetics of COVID-19 Patients with Different Disease Severities in Acute and Convalescent Phases: A 6-Month Follow-Up Study. Virol Sin. 2020 Dec;35(6):820-829. doi: 10.1007/s12250-020-00329-9. Epub 2020 Dec 22. PMID: 33351168; PMCID: PMC7754696.

29. Chen L, Abou-Alfa GK, Zheng B, Liu JF, Bai J, Du LT, Qian YS, Fan R, Liu XL, Wu L, Hou JL, Wang HY; PreCar Team. Genome-scale profiling of circulating cell-free DNA signatures for early detection of hepatocellular carcinoma in cirrhotic patients. Cell Res. 2021 May;31(5):589-592. doi: 10.1038/s41422-020-00457-7. Epub 2021 Feb 15. PMID: 33589745; PMCID: PMC8089097.

30. Wang HR, Gong MC, Sun JY, Sun J, Guo Y, Liu L, Zhu H. A new model for COVID-19 control and its implementation in the city of Honghu, China: a case report. Antimicrob Resist Infect Control. 2021 Feb 25;10(1):42. doi: 10.1186/s13756-021-00899-7. PMID: 33632318; PMCID: PMC7906241.

31. Wang T, Zhang X, Liu Z, Yao T, Zheng D, Gan J, Yu S, Li L, Chen P, Sun J (co-corresponding author). Single-cell RNA sequencing reveals the sustained immune cell dysfunction in the pathogenesis of sepsis secondary to bacterial pneumonia. Genomics. 2021 May;113(3):1219-1233. doi: 10.1016/j.ygeno.2021.01.026. Epub 2021 Mar 7. PMID: 33691144; PMCID: PMC7937330.

32. Zheng B, Liu XL, Fan R, Bai J, Wen H, Du LT, Jiang GQ, Wang CY, Fan XT, Ye YN, Qian YS, Wang YC, Liu GJ, Deng GH, Shen F, Hu HP, Wang H, Zhang QZ, Ru LL, Zhang J, Gao YH, Xia J, Yan HD, Liang MF, Yu YL, Sun FM, Gao YJ, Sun J, Zhong CX, Wang Y, Kong F, Chen JM, Zheng D, Yang Y, Wang CX, Wu L, Hou JL, Liu JF, Wang HY, Chen L. The Landscape of Cell-Free HBV Integrations and Mutations in Cirrhosis and Hepatocellular Carcinoma Patients. Clin Cancer Res. 2021 Jul 1;27(13):3772-3783. doi: 10.1158/1078-0432.CCR-21-0002. Epub 2021 May 4. PMID: 33947693.

33. Xu X, Nie S, Sun J (co-first author), Kong Y, Liang M, Li D, Ma T, Peng J, Gao S, Shao Y, Zha Y, Peng G, Ren C, Huang A, Hou FF. The Cumulative Rate of SARS-CoV-2 Infection in Chinese Hemodialysis Patients. Kidney Int Rep. 2020 Sep;5(9):1416-1421. doi: 10.1016/j.ekir.2020.07.010. Epub 2020 Jul 18. Erratum in: Kidney Int Rep. 2021 Sep;6(9):2525. Erratum in: Kidney Int Rep. 2021 Sep;6(9):2526-2531. PMID: 32838083; PMCID: PMC7368651.

34. Gu S, Wang W, Ye G, Chen C, Zhou Y, Guo L, Zhong S, Li X, Fu X, Wen C, Tang L, Sun J, Hou J, Li Y. Hepatocyte-derived L-carnitine restricts hepatitis B surface antigen loss through an immunosuppressive effect on germinal center-related immune cells. J Infect Dis. 2021 Jul 2:jiab344. doi: 10.1093/infdis/jiab344. Epub ahead of print. PMID: 34214150.

35. Xia M, Chi H, Wu Y, Hansen BE, Li Z, Liu S, Liao G, Zhang X, Zhou B, Hou J, Sun J, Janssen HLA, Peng J. Serum hepatitis B virus RNA level is associated with biochemical relapse in patients with chronic hepatitis B infection who discontinue nucleos(t)ide analogue treatment. Aliment Pharmacol Ther. 2021 Sep;54(5):709-714. doi: 10.1111/apt.16538. Epub 2021 Jul 18. PMID: 34275138.

36. Liu S, Deng R, Zhou B, Liang X, Liu Z, Peng J, Chen J, Zhou Y, Guo Y, Chen Y, Li W, Shen S, Lu X, Zhao S, Liao X, Liang H, Lan Y, Hou J, Fan R, Sun J (corresponding author). Association of serum hepatitis B virus RNA with hepatocellular carcinoma risk in chronic hepatitis B patients under nucleos(t)ide analogues therapy. J Infect Dis. 2021 Dec 21:jiab597. doi: 10.1093/infdis/jiab597. Epub ahead of print. PMID: 34931674.

37. Liu S, Wu Y, Deng R, Shen S, Fan R, Peng J, Li W, Liang X, Hou J, Sun J (co-corresponding author), Zhou B. Methodology-dependent performance of serum HBV RNA in predicting treatment outcomes in chronic hepatitis B patients. Antiviral Research. 2021,189, 105037.

38. Liu X, Zhao J, Wang H, Wang W, Su X, Liao X, Zhang S, Sun J (co-corresponding author), Zhang Z. Metabolic Defects of Peripheral T Cells in COVID-19 Patients. J Immunol. 2021 May 28:ji2100068. doi: 10.4049/jimmunol.2100068. Online ahead of print.

39. Li W, Deng R, Liu S, Guo H, Sun J (corresponding author). Letter to the Editor: Can the ratio of serum HBV RNA to DNA reflect the reverse transcription efficiency of viral pgRNA? Hepatology. 2021 Jul;74(1). doi: 10.1002/hep.31691.

40. Ma J, Cao H, Rodrigues RM, Xu M, Ren T, He Y, Hwang S, Feng D, Ren R, Yang P, Liangpunsakul S, Sun J (co-corresponding author), Gao B. Chronic-plus-binge alcohol intake induces production of proinflammatory mtDNA-enriched extracellular vesicles and steatohepatitis via ASK1/p38MAPKα-dependent mechanisms. JCI Insight. 2020 Jul 23;5(14):136496. doi: 10.1172/jci.insight.136496. PMID: 32544093.

41. Huang M, Liu X, Ye H, Zhao X, Zhao J, Liu Y, He X, Qu M, Pan J, Hou B, Cheng Y, Liu Z, Li Z, Liu L, Sun J (co-corresponding author), Zhang S, Zhang Z. Metabolic defects in splenic B cell compartments from patients with liver cirrhosis. Cell Death Dis. 2020 Oct 24; 11(10):915. doi: 10.1038/s41419-020-03060-1.

42. Liu S, Deng R, Zhou B, Sun J (corresponding author). Is World Health Organization HBV DNA Standard Appropriate for Standardizing Serum HBV RNA Assay? Clin Infect Dis. 2020 Oct 3:ciaa1503. doi: 10.1093/cid/ciaa1503.

43. Liu S, Li W, Sun J (corresponding author). Editorial: serum HBV RNA biphasic decline in patients with HBeAg-positive chronic hepatitis B treated with nucleos(t)ide analogues-authors' reply. Aliment Pharmacol Ther. 2020 Sep;52(5):883-884. doi: 10.1111/apt.15993.

44. Liu S, Huang Q, Zhou B, Guo H, Sun J (corresponding author). Reply to Letter to the Editor: Why serum HBV DNA has higher frequency of rtM204I/V mutation than serum HBV RNA in the same individual. Hepatology. 2021 May;73(5):2076-2077. doi: 10.1002/hep.31515.

45. Li W, Deng R, Liu S, Wang K, Sun J (corresponding author). Hepatitis B virus-related hepatocellular carcinoma in the era of antiviral therapy: The emerging role of non-viral risk factors. Liver Int. 2020 Oct;40(10):2316-2325. doi: 10.1111/liv.14607.

46. Sun J (first author and corresponding author), Aghemo A, Forner A, Valenti L. COVID-19 and liver disease. Liver Int. 2020 Jun;40(6):1278-1281. doi: 10.1111/liv.14470.

47. Fan R, Peng J, Xie Q, Tan D, Xu M, Niu J, Wang H, Ren H, Chen X, Wang M, Sheng J, Tang H, Bai X, Wu Y, Zhou B, Sun J (co-corresponding author), Hou J; Chronic Hepatitis B Study Consortium. Combining HBV RNA and hepatitis B core-related antigen: guidance for safely stopping nucleos(t)ide analogues in HBeAg-positive chronic hepatitis B patients. J Infect Dis. 2020 Jul 23;222(4):611-618. doi: 10.1093/infdis/jiaa136.

48. Li Y, Tang L, Guo L, Chen C, Gu S, Zhou Y, Ye G, Li X, Wang W, Liao X, Wang Y, Peng X, Liu G, Zhang X, Sun J, Peng J, Hou J. CXCL13-mediated recruitment of intrahepatic CXCR5+CD8+ T cells favors viral control in chronic HBV infection. J Hepatol. 2020 Mar;72(3):420-430. doi: 10.1016/j.jhep.2019.09.031.

49. Wang Y, Wong GLH, He FP, Sun J, Chan AWH, Yang JL, Shu SST, Liang XE, Tse YK, Fan XT, Hou JL, Chan HLY, Wong VSW. Quantifying and Monitoring Fibrosis in Non-Alcoholic Fatty Liver Disease Using Dual-Photon Microscopy. Gut. 2020 Jun;69(6):1116-1126. doi: 10.1136/gutjnl-2019-318841. Epub 2019 Sep 28.

50. Hou JL, Zhao W, Lee C, Hann HW, Peng CY, Tanwandee T, Morozov V, Klinker H, Sollano JD, Streinu-Cercel A, Cheinquer H, Xie Q, Wang YM, Wei L, Jia JD, Gong G, Han KH, Cao W, Cheng M, Tang X, Tan D, Ren H, Duan Z, Tang H, Gao Z, Chen S, Lin S, Sheng J, Chen C, Shang J, Han T, Ji Y, Niu J, Sun J, Chen Y, Cooney EL, Lim SG. Outcomes of Long-term Treatment of Chronic HBV Infection With Entecavir or Other Agents From a Randomized Trial in 24 Countries. Clin Gastroenterol Hepatol. 2020 Feb;18(2):457-467.e21. doi: 10.1016/j.cgh.2019.07.010.

51. Chen H, Sun J (co-first author), Zhou B, Peng J, Xie Q, Liang X, Fan R, Conran C, Xu J, Ji Y, Zhang X, Sun L, Jia J, Wang G, Hou J, Jiang DK. A missense variant in complement factor B (CFB) is a potential predictor of 24-week off-treatment response to PegIFNα therapy in Chinese HBeAg-positive chronic hepatitis B patients. Aliment Pharmacol Ther. 2020 Feb;51(4):469-478. doi: 10.1111/apt.15624.

52. Brouwer WP, Chan HLY, Lampertico P, Hou J, Tangkijvanich P, Reesink HW, Zhang W, Mangia A, Tanwandee T, Montalto G, Simon K, Ormeci N, Chen L, Tabak F, Gunsar F, Flisiak R, Ferenci P, Akdogan M, Akyuz F, Hirankarn N, Jansen L, Wong VW, Soffredini R, Liang X, Chen S, Groothuismink ZMA, Santoro R, Jaroszewicz J,, Ozaras R, Kozbial K, Brahmania M, Xie Q, Chotiyaputta W, Xun Q, Pazgan-Simon M, Oztas E, Verhey E, Montanari NR, Sun J, Hansen BE, Boonstra A, Janssen HLA,; GIANT-B Global Consortium. Genome-wide Association Study Identifies Genetic Variants Associated With Early and Sustained Response to (Pegylated) Interferon in Chronic Hepatitis B Patients: The GIANT-B Study. Clin Infect Dis. 2019 Nov 13;69(11):1969-1979. doi: 10.1093/cid/ciz084.

53. Shen S, Wong GL, Kuang Z, van Campenhout MJH, Fan R, Wong VW, Yip TC, Chi H, Liang X, Hu X, Lin W, Wu Y, Liu X, Boonstra A, Hou J, Sun J (co-corresponding author), Chan HL. Development and validation of a model for hepatitis B e antigen seroconversion in entecavir-treated patients with chronic hepatitis B. J Med Virol. 2020 Aug;92(8):1206-1213.. doi: 10.1002/jmv.25628.

54. Liu Z, Sun J, Hou J. Lower Risk of Hepatocellular Carcinoma with Tenofovir vs Entecavir in Patients With Chronic Hepatitis B. JAMA Oncology. 2019,5(6), 915-915.

55. Lucas ZH, Sun J (corresponding author). Letter to the editor: Early initiation of antiviral therapy contributes to a rapid and significant loss of serum HBsAg in infantile-onset hepatitis B. Journal of Hepatology, 2019,71:1263-1264

56. Fan R, Zhou B, Xu M, Tan D, Niu J, Wang H, Ren H, Chen X, Wang M, Ning Q, Shi G, Sheng J, Tang H, Bai X, Liu S, Lu F, Peng J, Sun J (co-corresponding author), Xie Q, Hou J; Chronic Hepatitis B Study Consortium. Association Between Negative Results From Tests for HBV DNA and RNA and Durability of Response After Discontinuation of Nucles(t)ide Analogue Therapy. Clin Gastroenterol Hepatol. 2020 Mar;18(3):719-727.e7. doi: 10.1016/j.cgh.2019.07.046.

57. Chen H, Sun J (co-first author), Zhou B, Xie Q, Liang X, Fan R, Conran C, Xu J, Ji Y, Zhang X, Sun L, Jia J, Wang G, Hou J, Jiang DK. Variants in STAT4 Associate With Cure of Chronic HBV Infection in HBeAg-positive Patients Treated With Pegylated Interferon-alpha. Clin Gastroenterol Hepatol. 2020 Jan;18(1):196-204.e8. doi: 10.1016/j.cgh.2019.04.044. Epub 2019 Apr 28.

58. Sun J, Ding H, Chen G, Wang G, Wei L, Zhang J, Xie Q, Wan M, Tang H, Chen S, Gao Z, Wang Y, Zhang D, Huang W, Sheng J, Ning Q, Yang D, Lu J, Pan C, Yang Y, Wang J, Sun C, Wang Q, Hou J. Sustained serological and complete responses in HBeAg-positive patients treated with Peginterferon alfa-2b: a 6-year long-term follow-up of a multicenter, randomized, controlled trial in China. BMC Gastroenterol. 2019 May 2;19(1):65. doi: 10.1186/s12876-019-0981-5.

59. Liu LZ, Sun J, Hou J, Chan HLY. Improvements in the management of chronic hepatitis B virus infection. Expert Rev Gastroenterol Hepatol. 2018 Nov,12(11), 1153-1166.

60. Tang L, Chen C, Gao X, Zhang W, Yan X, Zhou Y, Guo L, Zheng X, Wang W, Yang F, Liu G, Sun J, Hou J, Li Y. Interleukin-21 Reinvigorates the Antiviral Activity of Hepatitis B Virus (HBV)-Specific CD8+ T Cells in Chronic HBV Infection. J Infect Dis. 2019 Feb,219(5), 750-759.

61. Huang R, Rao H, Shang J, Chen H, Li J, Xie Q, Gao Z, Wang L, Wei J, Jiang J, Sun J, Jiang J, Wei L. A cross-sectional assessment of health-related quality of life in Chinese patients with chronic hepatitis c virus infection with EQ-5D. Health Qual Life Outcomes. 2018 Jun 15;16(1):124.

62. Chi H, Li Z, Hansen BE, Yu T, Zhang X, Sun J, Hou J, Janssen HLA, Peng J. Serum Level of Antibodies Against Hepatitis B Core Protein Is Associated With Clinical Relapse After Discontinuation of Nucleos(t)ide Analogue Therapy. Clin Gastroenterol Hepatol. 2019 Jan,17(1), 182-191.

63. Sun J (first author & corresponding author), Liang X, Fan R, Hou J. Editorial: sofosbuvir plus daclatasvir for the treatment of hepatitis C-can one size fit all?. Aliment Pharmacol Ther, 2018 Mar,47(6):853-854.

64. Yu R, Tan D, Ning Q, Niu J, Bai X, Chen S, Cheng J, Yu Y, Wang H, Xu M, Shi G, Wan M, Chen X, Tang H, Sheng J, Dou X, Shi J, Ren H, Wang M, Zhang H, Gao Z, Chen C, Ma H, Jia J, Hou J, Xie Q, Sun J (corresponding author). Association of baseline vitamin D level with genetic determinants and virologic response in patients with chronic hepatitis B. Hepatol Res, 2018 Feb;48(3):E213-E221.

65. Shen S, Liang X, Hamed K, Tanaka Y, Omagari K, Fan R, Xie Q, Tan D, Zhou B, Jia JD, Hou J, Sun J (corresponding author). Effect of hepatitis B virus subgenotype on antiviral response in nucleoside-treated hepatitis B envelope antigen-positive patients. Hepatol Res, 2018 Feb;48(2):134-143.

66. Wang Y, Liang X, Yang J, Wang H, Tan D, Chen S, Cheng J, Chen Y, Sun J, Rong F, Yang W, Liu H, Liu Z, Zheng Y, Liang J, Li S, Liu Z, Hou J. Improved performance of quantitative collagen parameters versus standard histology in longitudinal assessment of nonadvanced liver fibrosis for chronic hepatitis B. J Viral Hepat. 2018 May;25(5):598-607.

67. Liang X, Xie Q, Tan D, Ning Q, Niu J, Bai X, Chen S, Cheng J, Yu Y, Wang H, Xu M, Shi G, Wan M, Chen X, Tang H, Sheng J, Dou X, Shi J, Ren H, Wang M, Zhang H, Gao Z, Chen C, Ma H, Chen Y, Fan R, Sun J (co-corresponding author), Jia J, Hou J. Interpretation of liver stiffness measurement-based approach for the monitoring of hepatitis B patients with antiviral therapy: a 2-year prospective study. J Viral Hepat, 2018 Mar;25(3):296-305

68. Hou J, Wang G, Wang F, Cheng J, Ren H, Zhuang H, Sun J, Li L, Li J, Meng Q, Zhao J, Duan Z, Jia J, Tang H, Sheng J, Peng J, Lu F, Xie Q, Wei L; Chinese Society of Hepatology, Chinese Medical Association; Chinese Society of Infectious Diseases, Chinese Medical Association. Guideline of Prevention and Treatment for Chronic Hepatitis B (2015 Update). J Clin Transl Hepatol. 2017 Dec 28;5(4):297-318.

69. Ning L, Lin W, Hu X, Fan R, Liang X, Wu Y, Shen S, Yu R, Sun J (co-corresponding author), Hou J. Prevalence of chronic kidney disease in patients with chronic hepatitis B: A cross-sectional survey. J Viral Hepat, 2017 Nov;24(11):1043-1051.

70. Ge J, Huang Z, Liu H, Chen J, Xie Z, Chen Z, Peng J, Sun J, Hou J, Zang X. Lower Expression of MicroRNA-155 Contributes to Dysfunction of Natural Killer Cells in Patients with Chronic Hepatitis B. Front Immunol, 2017 Sep 22；8:1173.

71. Xu Y, Liu Y, Zhao M, Chen Y, Xie C, Gong M, Deng H, Li X, Sun J, Hou J, Wu H, Wang Z. Dynamic Perturbations of CD4 and CD8 T Cell Receptor Repertoires in Chronic Hepatitis B Patients upon Oral Antiviral Therapy. Front Immunol. 2017 Sep 14;8:1142.

72. Liu C, Huang X, Werner M, Broering R, Ge J, Li Y, Liao B, Sun J, Peng J, Lu M, Hou J, Zhang X. Elevated Expression of Chemokine CXCL13 in Chronic Hepatitis B Patients Links to Immune Control during Antiviral Therapy. Front Immunol. 2017 Mar 23;8:323.

73. Cao J, Chi H, Yu T, Li Z, Hansen BE, Zhang X, Zhong C, Sun J, Hou J, Janssen H, Peng J. Off-Treatment Hepatitis B Virus (HBV) DNA Levels and the Prediction of Relapse After Discontinuation of Nucleos(t)ide Analogue Therapy in Patients With Chronic Hepatitis B: A Prospective Stop Study. J Infect Dis, 2017 Feb,215(4):581-589.

74. Deng G, Ge J, Liu C, Pang J, Huang Z, Peng J, Sun J, Hou J, Zhang X. Impaired expression and function of TLR8 in chronic HBV infection and its association with treatment responses during peg-IFN-alpha-2a antiviral therapy. Clin Res Hepatol Gastroenterol, 2017 Sep,41(4):386-398.

75. Peng Y, Li Y, Hou J, Sun J, Su M, Li Y, Xiang K, Yan L, Zhuang H, LI T. The nucleotide changes within HBV core promoter/precore during the first 12 weeks of nucleos(t)ide treatment might be associated with a better virological response. Infect Genet Evol, 2017,49:116-121.

76. Pang J, Zhang G, Lin Y, Xie Z, Liu H, Tang L, Lu M, Yan R, Guo H, Sun J, Hou J, Zhang X. Transforming growth factor β-activated kinase 1 transcriptionally suppresses hepatitis B virus replication. Sci Rep. 2017 Jan 3;7:39901.

77. Dong H, Zhou B, Kang H, Jin W, Zhu Y, Shen Y, Sun J, Wang S, Zhao G, Hou J, He Y. Small surface antigen variants of HBV associated with responses to telbivudine treatment in chronic hepatitis B patients. Antivir Ther, 2017,22(1):43-51.

78. Wang C, Ji D, Chen J, Shao Q, Li B, Liu J, Wu V, Wong A, Wang Y, Zhang X, Lu L, Wong C, Tsang S, Zhang Z, Sun J, Hou J, Chen G, Lau G. Hepatitis due to Reactivation of Hepatitis B Virus in Endemic Areas Among Patients With Hepatitis C Treated With Direct-acting Antiviral Agents. Clin Gastroenterol Hepatol. 2017 Jan;15(1):132-136.

79. Lau G, Benhamou Y, Chen G, Li J, Shao Q, Ji D, Li F, Li B, Liu J, Hou J, Sun J, Wang C, Chen J, Wu V, Wong A, Wong CL, Tsang ST, Wang Y, Bassit L, Tao S, Jiang Y, Hsiao HM, Ke R, Perelson AS, Schinazi RF. Efficacy and safety of 3-week response-guided triple direct-acting antiviral therapy for chronic hepatitis C infection: a phase 2, open-label, proof-of-concept study. Lancet Gastroenterol Hepatol. 2016 Oct;1(2):97-104.

80. Fan R, Sun J, Hou J. Combination Therapy With Tenofovir and Peginterferon May Not Be Translated Into Current Clinical Practice. Gastroenterology. 2016 May;150(5):1253-1254.

81. Zhou B, Dong H, He Y, Sun J (co-first author), Jin W, Xie Q, Fan R, Wang M, Li R, Chen Y, Xie S, Shen Y, Huang X, Wang S, Lu F, Jia J, Zhuang H, Locarnini S, Zhao GP, Jin L, Hou J. Composition and Interactions of Hepatitis B Virus Quasispecies Defined the Virological Response During Telbivudine Therapy. Sci Rep, 2015 Nov 24;5:17123.

82. Yu R, Sun J (co-first author), Zheng Z, Chen J, Fan R, Liang X, Zhu Y, Liu Y, Shen S, Hou J. Association between vitamin D level and viral load or fibrosis stage in chronic hepatitis B patients from Southern China. J Gastroenterol Hepatol, 2015 Mar;30(3):566-574.

83. Liang X, Fan R, Sun J, Shaikh J, Taneja A, Gupta S, Hamed K. Effect of Telbivudine Versus Other Nucleos(t)ide Analogs on HBeAg Seroconversion and Other Outcomes in Patients with Chronic Hepatitis B: A Network Meta-Analysis. Adv Ther, 2016 Apr,33(4):519-531.

84. Peng J, Cai S, Yu T, Chen Y, Zhu Y, Sun J. Aspartate aminotransferase to platelet ratio index - a reliable predictor of therapeutic efficacy and improvement of Ishak score in chronic hepatitis B patients treated with nucleoside analogues. Scand J Clin Lab Invest. 2016;76(2):133-142.

85. Hao R, Xiang K, Peng Y, Hou J, Sun J, Li Y, Su M, Yan L, Zhuang H, Li T. Naturally occurring deletion/insertion mutations within HBV whole genome sequences in HBeAg-positive chronic hepatitis B patients are correlated with baseline serum HBsAg and HBeAg levels and might predict a shorter interval to HBeAg loss and seroconversion during antiviral treatment. Infect Genet Evol, 2015 Jul;33:261-268.

86. Li Y, Wang W, Tang L, He X, Yan X, Zhang X, Zhu Y, Sun J, Shi Y, Ma X, Mackay IR, Gershwin ME, Han Y, Hou J. Chemokine (C-X-C motif) ligand 13 promotes intrahepatic chemokine (C-X-C motif) receptor 5+ lymphocyte homing and aberrant B-cell immune responses in primary biliary cirrhosis. Hepatology, 2015 Jun;61(6):1998-2007.

87. Peng Y, Liu B, Hou J, Sun J, Hao R, Xiang K, Yan L, Zhang J, Zhuang H, Li T. Naturally occurring deletions/insertions in HBV core promoter tend to decrease in hepatitis B e antigen-positive chronic hepatitis B patients during antiviral therapy. Antivir Ther, 2015;20(6):623-632.

88. Liang X, Cheng J, Sun Y, Chen X, Li T, Wang H, Jiang J, Chen X, Long H, Tang H, Yu Y, Sheng J, Chen S, Niu J, Ren H, Shi J, Dou X, Wan M, Jiang J, Xie Q, Shi G, Ning Q, Chen C, Tan D, Ma H, Sun J, Jia J, Zhuang H, Hou J. Randomized, Three-arm Study to Optimize Lamivudine Efficacy in HBeAg Positive Chronic Hepatitis B Patients. J Gastroenterol Hepatol, 2015 Apr;30(4):748-755

89. Peng J, Cao J, Yu T, Cai S, Li Z, Zhang X, Sun J. Predictors of sustained virologic response after discontinuation of nucleos(t)ide analog treatment for chronic hepatitis B. Saudi J Gastroenterol, 2015 Jul-Aug,21(4):245-253.

90. Huang Z, Ge J, Pang J, Liu H, Chen J, Liao B, Huang X, Zuo D, Sun J, Lu M, Zhang, X, Hou J. Aberrant expression and dysfunction of TLR2 and its soluble form in chronic HBV infection and its regulation by antiviral therapy. Antiviral Res, 2015 Jun,118:10-19.

91. Yang G, Han M, Chen F, Xu Y, Chen E, Wang X, Liu Y, Sun J, Hou J, Ning Q, Wang Z. Hepatitis B virus genotype B and mutations in basal core promoter and pre-core/core genes associated with acute-on-chronic liver failure: a multicenter cross-sectional study in China. Hepatol Int, 2014 Oct;8(4):508-516.

92. Xu S, Wang Y, Tai DC, Wang S, Cheng CL, Peng Q, Yan J, Chen Y, Sun J, Liang X, Zhu Y, Rajapakse JC, Welsch RE, So PT, Wee A, Hou J, Yu H. qFibrosis: a fully-quantitative innovative method incorporating histological features to facilitate accurate fibrosis scoring in animal model and chronic hepatitis B patients. J Hepatol, 2014 Aug;61(2):260-269.

93. Lai Q, Ma S, Ge J, Huang Z, Huang X, Jiang X, Li Y, Zhang M, Zhang X, Sun J, Abbott WG, Hou J. TCRγδ(+)CD4(-)CD8(-) T Cells Suppress the CD8(+) T-Cell Response to Hepatitis B Virus Peptides, and Are Associated with Viral Control in Chronic Hepatitis B. PLoS One, 2014 Feb 14;9(2):e88475.

94. Rao H, Wei L, Lopez-Talavera JC, Shang J, Chen H, Li J, Xie Q, Gao Z, Wang L, Wei J, Jiang J, Sun Y, Yang R, Li H, Zhang H, Gong Z, Zhang L, Zhao L, Dou X, Niu J, You H, Chen Z, Ning Q, Gong G, Wu S, Ji W, Mao Q, Tang H, Li S, Wei S, Sun J, Jiang J, Lu L, Jia J, Zhuang H. Distribution and clinical correlates of viral and host genotypes in Chinese patients with chronic hepatitis C virus infection. J Gastroenterol Hepatol, 2014 Mar,29(3):545-553.

95. He J, Chen X, Sun J. Oral Wounds and Hepatitis B Virus Transmission. Infect Control Hosp Epidemiol. 2014 Aug;35(8):1079-80. doi: 10.1086/677171.

96. Li Y, Ma S, Tang L, Li Y, Wang W, Huang X, Lai Q, Zhang M, Sun J, Li CK, Abbott WG, Naoumov NV, Zhang Y, Hou J. Circulating chemokine (C-X-C Motif) receptor 5(+) CD4(+) T cells benefit hepatitis B e antigen seroconversion through IL-21 in patients with chronic hepatitis B virus infection. Hepatology, 2013 Oct;58(4):1277-1286.

97. Sun J (first author & co-corresponding author), Liang X, Wong VW. Commentary: prognostication of chronic hepatitis B--are Fibrotest and Fibroscan the final answers? Aliment Pharmacol Ther, 2013 Jun;37(11):1113.

98. Zhou B, Liu MS, Lv GT, Zeng HK, Wang YJ, Sun J (corresponding author), Hou JL. Quantification of Hepatitis B Surface Antigen and E Antigen: Correlation between Elecsys and Architect Assays. J Viral Hepat, 2013 Jun;20(6):422-429..

99. Wang C, Fan R, Sun J, Hou J. Prevention and management of drug resistant hepatitis B virus infections. J Gastroenterol Hepatol,2012 Sep;27(9):1432-1440.

100. Zhou B, Wang Z, Yang J, Sun J, Li H, Tanaka Y, Mizokami M, Hou J. Novel evidence of HBV recombination in family cluster infections in western China. PLoS One, 2012;7(6):e38241.

101. Ma SW, Huang X, Li YY, Tang LB, Sun XF, Jiang XT, Zhang YX, Sun J, Liu ZH, Abbott WG, Dong YH, Naoumov NV, Hou JL. High serum IL-21 levels after 12 weeks of antiviral therapy predict HBeAg seroconversion in chronic hepatitis B. J Hepatol, 2012 Apr;56(4):775-781.

102. Jiang X, Zhang M, Lai Q, Huang X, Li Y, Sun J, Abbott WG, Ma S, Hou J. Restored circulating invariant NKT cells are associated with viral control in patients with chronic hepatitis B. PLoS One,2011;6(12):e28871.

103. Xiao L, Zhou B, Gao H, Ma S, Yang G, Xu M, Abbott WG, Chen J, Sun J, Wang Z, Hou J. Hepatitis B virus genotype B with G1896A and A1762T/G1764A mutations is associated with hepatitis B related acute-on-chronic liver failure. J Med Virol, 2011 Sep;83(9):1544-1550.

104. Sun J, Hou J, Xie Q, Li X, Zhang J, Wang Y, Wang H, Lai J, Chen S, Jia J, Sheng J, Chan H, Wang J, Li M, Jiang M, Sung J. Randomised clinical trial: efficacy of peginterferon alfa-2a in HBeAg positive chronic hepatitis B patients with lamivudine resistance. Aliment Pharmacol Ther, 2011 Aug;34(4):424-431.

105. Hu X, Ma S, Huang X, Jiang X, Zhu X, Gao H, Xu M, Sun J, Abbott WG, Hou J. Interleukin-21 is upregulated in hepatitis B-related acute-on-chronic liver failure and associated with severity of liver disease. J Viral Hepat, 2011 Jul;18(7):458-467.

106. Liang M, Ma S, Hu X, Zhou B, Zhang J, Chen J, Wang Z, Sun J, Zhu X, Abbott W, Hou J. Cellular immune responses in patients with hepatitis B surface antigen seroclearance induced by antiviral therapy. Virol J, 2011 Feb 14;8:69.

107. Ma SW, Li YY, Zhang GW, Huang X, Sun J, Li C, Abbott WG, Hou JL. Complementarity-determining region 3 size spectratypes of T cell receptor beta chains in CD8+ T cells following antiviral treatment of chronic hepatitis B. Antimicrob Agents Chemother, 2011 Feb;55(2):888-894.

108. Sun J, Hou JL. Management of chronic hepatitis B: experience from China. Journal of Viral Hepatitis, 2010; 17 (suppl 1): 10-17

109. Chen J, Wang Z, Guo Y, Peng J, Sun J, Ahmed CS, Zhou Y, Hou J. Serum HBsAg changes in HBeAg positive chronic hepatitis B patients with continuous viral load reductions during treatment with adefovir or peg-interferon-alpha-2a. Antiviral Res, 2009 Jan;81(1):88-91.

110. Hui CK, Sun J, Au WY, Lie AK, Yueng YH, Zhang HY, Lee NP, Hou JL, Liang R, Lau GK. Occult hepatitis B virus infection in hematopoietic stem cell donors in a hepatitis B virus endemic area. J Hepatol, 2005 Jun;42(6):813-819.

111. Hui CK, Lie A, Au WY, Ma SY, Leung YH, Zhang HY, Sun J, Cheung WW, Chim CS, Kwong YL, Liang R, Lau GK. Effectiveness of prophylactic Anti-HBV therapy in allogeneic hematopoietic stem cell transplantation with HBsAg positive donors. Am J Transplant, 2005 Jun;5(6):1437-1445.

112. Sun J, Wang Z, Ma S, Zeng G, Zhou Z, Luo K, Hou J. Clinical and virological characteristics of lamivudine resistance in chronic hepatitis B patients: a single center experience. J Med Virol, 2005 Mar;75(3):391-398

113. Zeng GB, Wen SJ, Wang ZH, Yan L, Sun J, Hou JL. A novel hepatitis B virus genotyping system by using restriction fragment length polymorphism patterns of S gene amplicons. World J Gastroenterol, 2004 Nov 1;10(21):3132-3136.

114. Wang Z, Zhang J, Yang H, Li X, Wen S, Guo Y, Sun J, Hou J. Quantitative analysis of HBV DNA level and HBeAg titer in hepatitis B surface antigen positive mothers and their babies: HBeAg passage through the placenta and the rate of decay in babies. J Med Virol, 2003 Nov;71(3):360-366.

115. Hou J, Wang Z, Cheng J, Lin Y, Lau GK, Sun J, Zhou F, Waters J, Karayiannis P, Luo K. Prevalence of naturally occurring surface gene variants of hepatitis B virus in nonimmunized surface antigen-negative Chinese carriers. Hepatology, 2001 Nov;34(5):1027-1034

四、论著之外的代表性研究成果和学术奖励

(1) 延缓慢性肝脏疾病进展防控体系的创新突破和推广应用，广东省科技进步一等奖，2023年7月，孙剑（排名第1）

(2) 广东省丁颖科技奖，2021年5月；

(3) 第十一届吴孟超医学青年基金奖，2018年8月；

(4) 慢性乙型肝炎诊疗体系的创新及关键技术推广应用，国家科技进步二等奖2015年12月，孙剑（排名第4）；

(5) 慢性乙型肝炎和脂肪性肝病的防诊治系列创新及其推广应用，广东省科技进步一等奖，2017年12月，孙剑（排名第1）；

(6) 慢性乙型肝炎优化抗病毒治疗及影响疗效的因素，中华医学科技二等奖, 2014年12月，孙剑（排名第2）；

(7) 乙型肝炎病毒基因型和耐药性研究，广东省科技进步一等奖，2009年3月，孙剑（排名第4）；

(8) 乙肝病毒分子病毒学基础与临床，广东省科技进步一等奖，2004年5月，孙剑（排名第6）；

(9) 乙肝病毒基因组变异的临床和生物学意义, 中华医学会科技二等奖, 2003.1.5，孙剑（排名第6）；

(10) 乙肝病毒变异对临床诊断、抗病毒治疗的影响, 军队医疗成果二等奖，2003年2月，孙剑（排名第7）

(11) 第23届亚太肝病学年会“Young Investigator Awards”，2013.年6月；

(12) 第22届亚太肝病学年会“Young Investigator Awards”，2012年2月。